 |
New warnings on Novartis MS pillEuropean and US regulators have backed the continued use of Novartis AG's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, but said the drug needed to carry stronger warnings on heart risks. Novartis said More… |
 |
Bahrain licences first MS oral drugBahrain has licensed the world’s first oral medication for Multiple Sclerosis (MS), a nervous system disease that affects the brain and spinal cord leading to symptoms such as visual disturbances and muscle weakness. The Bahrain Ministry o More… |
 |
Novartis gets US backing for MS pillSwiss drugmaker Novartis AG's multiple sclerosis pill Gilenya won US backing, putting it ahead of German rival Merck KGaA in the race to be first with an oral treatment in the United States. The US Food and Drug Administration's back More… |
